Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium

Vinflunine is the only cytotoxic agent tested as a second line therapy in transitional cell carcinoma of the urothelium in a phase III trial. It is not largely employed in clinical practice because of the high incidence of grade 3–4 toxicity. We evaluated efficacy and safety of Vinflunine at the dos...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Schinzari, Giovanni, Rossi, Ernesto, Pierconti, Francesco, Garufi, Giovanna, Monterisi, Santa, Strippoli, Antonia, D’Argento, Ettore, Cassano, Alessandra, Barone, Carlo
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2018
Matèries:
Clinical Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5823567/
https://ncbi.nlm.nih.gov/pubmed/29492236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24162
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars